Healio
›
Hematology/Oncology
›
Hematologic Malignancies
›
News
-
In the Journals
-
-
May 8, 2013
-
Salvage autologous stem cell transplantation in combination with novel chemotherapy agents was associated with improved survival in a cohort of patients...More
»
-
In the Journals
-
-
May 6, 2013
-
Barasertib was associated with improved survival and manageable toxicity compared with low-dose cytosine arabinoside in a cohort of patients with acute...More
»
-
FDA approvals
Perspective
-
-
May 1, 2013
-
Janssen Research and Development announced that the FDA has granted breakthrough therapy designation to daratumumab for the treatment of multiple myeloma.
...More
»
-
In the Journals
-
-
May 1, 2013
-
Children of mothers who drank coffee daily during pregnancy were at an increased risk for acute leukemia, according to study results.
Researchers conducted...More
»
-
-
-
HemOnc Today, May 10, 2013
-
The FDA granted breakthrough therapy designation for ibrutinib as monotherapy for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma...More
»
-
Cover Stories
-
-
HemOnc Today, May 10, 2013
-
After more than 3 decades of intense research, nanotechnology has moved out of the fiction realm and into the scientific.
Preliminary data suggest...More
»
-
In Practice
-
-
HemOnc Today, May 10, 2013
-
William Wood
As a stem cell transplantation physician, I come across clinical scenarios all the time in which the “correct” course of action isn’t...More
»
-
In the Journals
Perspective
-
-
April 26, 2013
-
The omission of radiotherapy in pediatric patients in complete remission after chemotherapy for early-stage Hodgkin’s lymphoma appeared safe and...More
»
-
In the Journals
-
-
April 24, 2013
-
Four cycles of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine led to a significant dose reduction, delay in treatment, toxicity and...More
»
-
In the Journals
Perspective
-
-
April 16, 2013
-
Researchers who evaluated three rituximab-containing regimens among patients with follicular lymphoma reported rituximab plus cyclophosphamide,...More
»